Scancell, Poolbeg Pharma, Optima Health, SkinBioTherapeutics - Healthcare Week in Review
Автор: Proactive Investors
Загружено: 2025-12-12
Просмотров: 65
Описание:
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) announced great clinical data from its SCOPE melanoma trial for iSCIB1+. The drug showed a 74% progression-free survival rate at 16 months, beating the standard-of-care benchmark.
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) is the lead business partner in the new £3.4 million RISE research program. This initiative will focus on cytokine release syndrome (CRS), making its POLB 001 trial a central component.
Optima Health PLC (AIM:OPT) posted strong first-half results, achieving 17% revenue growth driven by both organic expansion and new acquisitions. The company is also mobilising its massive £210 million contract for the UK Armed Forces.
SkinBioTherapeutics PLC (AIM:SBTX) is celebrating a fantastic year, with revenue surging by 284% to £4.6 million. The company is boosting growth through new retail deals and integrating recent strategic acquisitions.
Follow us and subscribe on YouTube, our social channels and on proactiveinvestors.co.uk.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
